Oncolytic HSV Isolate Selection for Stronger Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic therapies with viruses like HSV do not effectively target all tumors and patients, lacking sufficient direct oncolytic and immune-stimulating effects, and often require pre-existing immune responses and inflamed tumor microenvironments for optimal efficacy.
Innovation Solution
Selecting clinical isolates of viruses from natural populations for their superior tumor cell killing abilities and modifying them to express fusogenic proteins and immune stimulatory molecules, enhancing direct oncolytic effects and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oncolytic viruses like HSV are used, then the therapy can be administered, but the direct oncolytic effects and immune-stimulating effects are insufficient
Solution Approach 1:
The patent applies parameter changes by selecting clinical isolates of HSV-1 with superior tumor cell killing abilities compared to conventional strains, and by modifying viral genes to express fusogenic proteins and immune stimulatory molecules at optimized levels, thereby enhancing both direct oncolytic effects and immune stimulation
Solution Approach 2:
The patent creates composite viral structures by engineering HSV-1 to co-express multiple therapeutic components including fusogenic proteins (for enhanced cell fusion and spread) and immune stimulatory molecules (for potentiated immune responses), combining multiple functions into a single oncolytic virus platform
2Adaptability or versatility
If conventional oncolytic viruses are used, then treatment can proceed, but pre-existing immune responses and inflamed tumor microenvironments are required for optimal efficacy
Solution Approach 1:
The patent implements self-service by engineering the oncolytic virus to autonomously create an inflamed tumor microenvironment through expression of immune stimulatory molecules, eliminating the requirement for pre-existing immune responses and enabling the therapy to function independently across diverse tumor types
Solution Approach 2:
The patent achieves universality by developing an oncolytic virus platform with multi-functional capabilities including tumor cell lysis, immune stimulation, and microenvironment modulation, making it applicable across different cancer types without requiring specific pre-existing immune conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improved oncolytic viruses demonstrate enhanced tumor cell killing, increased antigen release, and potentiated immune responses, offering better therapeutic outcomes, including synergies with immune checkpoint blockade and IDO inhibition.
Implementation Method 1
Viral genes are expressed and the virus replicates. This usually results in the death of the infected cell and the release of the antigenic components of the cell as the cell ruptures as it dies.
Implementation Method 2
Viruses also engage with various mediators of the innate immune response as part of the host response to the recognition of a viral infection through e.g. toll-like receptors and cGAS/STING signalling resulting in the activation of interferon responses and inflammation
Data Source
AI summary
The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.